| Dr David Stewart Boggs, MD | |
|
4334 Nw Expressway, Suite 214, Oklahoma City, OK 73116-1578 | |
| (405) 753-6200 | |
| (405) 753-6090 |
| Full Name | Dr David Stewart Boggs |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 35 Years |
| Location | 4334 Nw Expressway, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982656385 | NPI | - | NPPES |
| 100110590A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | 18543 (Oklahoma) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | 18543 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Integris Baptist Medical Center, Inc | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integris Ambulatory Care Corporation | 2365408465 | 382 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
An approach designed to reduce HIV/STDs previously used exclusively by academic researchers has successfully been implemented by community-based organizations (CBOs), an important component in national strategies to curtail the spread of HIV, meaning far more "at risk" youths can be reached.
Sound Physicians, a leading hospitalist organization focused on driving improvements in quality, satisfaction and financial performance of inpatient healthcare delivery, announced today an agreement to provide hospitalist services at San Joaquin Community Hospital in Bakersfield, Calif.
Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
The Association of Hispanic Healthcare Executives and the National Hispanic Chamber of Commerce on Health today announced the launching of their social media campaign, which will partner Hispanic media, the country's leading Hispanic professional health associations and Hispanic consumers.
› Verified 7 days ago
| Entity Name | Integris Ambulatory Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750333936 PECOS PAC ID: 2365408465 Enrollment ID: O20041209000354 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
An approach designed to reduce HIV/STDs previously used exclusively by academic researchers has successfully been implemented by community-based organizations (CBOs), an important component in national strategies to curtail the spread of HIV, meaning far more "at risk" youths can be reached.
Sound Physicians, a leading hospitalist organization focused on driving improvements in quality, satisfaction and financial performance of inpatient healthcare delivery, announced today an agreement to provide hospitalist services at San Joaquin Community Hospital in Bakersfield, Calif.
Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
The Association of Hispanic Healthcare Executives and the National Hispanic Chamber of Commerce on Health today announced the launching of their social media campaign, which will partner Hispanic media, the country's leading Hispanic professional health associations and Hispanic consumers.
› Verified 7 days ago
| Entity Name | Zuhdi Transplant Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942242623 PECOS PAC ID: 6507873403 Enrollment ID: O20060317000435 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
An approach designed to reduce HIV/STDs previously used exclusively by academic researchers has successfully been implemented by community-based organizations (CBOs), an important component in national strategies to curtail the spread of HIV, meaning far more "at risk" youths can be reached.
Sound Physicians, a leading hospitalist organization focused on driving improvements in quality, satisfaction and financial performance of inpatient healthcare delivery, announced today an agreement to provide hospitalist services at San Joaquin Community Hospital in Bakersfield, Calif.
Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
The Association of Hispanic Healthcare Executives and the National Hispanic Chamber of Commerce on Health today announced the launching of their social media campaign, which will partner Hispanic media, the country's leading Hispanic professional health associations and Hispanic consumers.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Stewart Boggs, MD 4334 Nw Expressway, Suite 214, Oklahoma City, OK 73116-1578 Ph: (405) 753-6200 | Dr David Stewart Boggs, MD 4334 Nw Expressway, Suite 214, Oklahoma City, OK 73116-1578 Ph: (405) 753-6200 |
News Archive
Æterna Zentaris Inc. (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that on January 21, 2010, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the minimum closing bid price of its common shares had fallen below US$1.00 for 30 consecutive trading days, and therefore, Æterna Zentaris was not in compliance with NASDAQ Listing Rule 5450(a)(1) (the "Rule").
An approach designed to reduce HIV/STDs previously used exclusively by academic researchers has successfully been implemented by community-based organizations (CBOs), an important component in national strategies to curtail the spread of HIV, meaning far more "at risk" youths can be reached.
Sound Physicians, a leading hospitalist organization focused on driving improvements in quality, satisfaction and financial performance of inpatient healthcare delivery, announced today an agreement to provide hospitalist services at San Joaquin Community Hospital in Bakersfield, Calif.
Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), today announced that the U.S. Food and Drug Administration approved LONSURF (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
The Association of Hispanic Healthcare Executives and the National Hispanic Chamber of Commerce on Health today announced the launching of their social media campaign, which will partner Hispanic media, the country's leading Hispanic professional health associations and Hispanic consumers.
› Verified 7 days ago
Evelyn Lorents, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 920 Sl Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Patrick Bronson Reeves, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3366 Nw Expressway Ste 550, Oklahoma City, OK 73112 Phone: 405-942-5442 Fax: 405-942-6448 | |
Dr. Jake Lee Evans, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Aat 6300, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Metri Haddaden, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 800 Stanton L Young Blvd # 8425, Oklahoma City, OK 73104 Phone: 405-271-6173 Fax: 410-554-2184 | |
Divya Sharma Divyadarshini, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 800 Stanton L Young Blvd, Oklahoma City, OK 73104 Phone: 405-271-5963 | |
Dr. Philip Barton Miner, Jr., M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1000 N Lincoln Blvd, Suite 210, Oklahoma City, OK 73104 Phone: 405-271-4644 Fax: 405-271-3296 | |
Gary Lee Worcester, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St, Ste 400, Oklahoma City, OK 73112 Phone: 405-947-3341 |